TILT Biotherapeutics Reports Results for TILT-123 in P-I Trial for the Treatment of Solid Tumors at SITC 2023
Shots:
- The P-I (TUNIMO) trial evaluates the safety of TILT-123 monotx. in patients (n=20) with advanced solid tumors incl. sarcomas (35%), melanoma (15%) & ovarian cancer (10%), etc. who were refractory to standard therapy
- The results showed a significant safety & efficacy result incl. anti-tumor activities & the induction of immune responses across different cancers. The results were presented in four posters at the SITC 2023
- Moreover, an equally positive tolerability was seen with TILT-123 vs other oncolytic viral therapies, allowing TILT-123 to be assessed in other combination trials (NCT04217473, NCT05271318, NCT05222932). TILT-123 is a T-cell activating oncolytic adenovirus that encodes for interleukin-2 (IL-2)
Ref: GLOBE Newswire | Image: TILT Biotherapeutics
Related News:- Tilt Biotherapeutics Signs an Agreement with Merck KGaA and Pfizer to Investigate the Dual Combination for Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
